Mesoblast GvHD Stem Cell Treatment Set For Filing In Japan
This article was originally published in PharmAsia News
Executive Summary
Australia's Mesoblast expects Japan review to begin soon on its proprietary JR-031 mesenchymal stem cells for treating steroid-refactory acute graft versus host disease, which is potentially life-threatening.